keyword
https://read.qxmd.com/read/38443123/survey-of-the-prices-of-topical-compounded-medications-for-alopecia-in-the-tri-state-area
#21
JOURNAL ARTICLE
Janet Choi, Kelly Hawkins, Eliza Balazic, Shaveonte Graham, Chesahna Kindred, Kseniya Kobets
BACKGROUND: Currently, there is only one topical medication approved by the U.S. Food and Drug Administration for alopecia, minoxidil 2.5% and 5%. With limited options, dermatologists often turn to compounding pharmacies for customized topical alopecia medications. OBJECTIVES: (1) to investigate the pricing and availabilities of compounded topical alopecia medications and (2) to investigate the delivery/mail options available. METHODS: 103 dermatological compounding pharmacies in the tri-state area were contacted...
March 1, 2024: Journal of Drugs in Dermatology: JDD
https://read.qxmd.com/read/38429078/study-of-therapeutic-patient-education-practices-in-french-renal-transplantation-centres
#22
JOURNAL ARTICLE
Camille Boissiere, Tristan Rallon, Cécile Vigneau, Elouan Demay, Claire Chatron, Astrid Bacle
OBJECTIVES: Therapeutic patient education (TPE) plays a critical role in the management of kidney transplant recipients. However, discrepancies exist in the guidance provided regarding the usage of immunosuppressants across different kidney transplant centres in France. METHODS: To assess the current landscape of TPE practices in this patient population, an online questionnaire consisting of 51 questions was distributed to 32 French renal transplantation centres...
March 1, 2024: European Journal of Hospital Pharmacy. Science and Practice
https://read.qxmd.com/read/38410340/tacrolimus-ointment-in-periorbital-atopic-dermatitis
#23
Mazen Alzahrani, Yumna F Kamal, Muhammad A Akram
Periorbital atopic dermatitis (AD) is a common sign in ophthalmological practice and usually has a persistent and relapsing course. Treatment with topical corticosteroids has various side effects associated with their usage. Tacrolimus topical ointment has unique immunomodulatory properties that decrease skin inflammation and pruritus in AD. In this case series, we present a prospective case series of five patients (three males and two females) who received topical application of tacrolimus ointment 0.1-0.03% in the periorbital area twice daily for one to four weeks...
January 2024: Curēus
https://read.qxmd.com/read/38371137/the-management-of-plaque-psoriasis-with-halobetasol-and-tacrolimus-combination-therapy-versus-calcipotriol-monotherapy-a-case-report
#24
Mohammed Z Sarwar, Nawaid H Khan, MIrza Masroor Ali Beg, Niloufer Mariam Javeed Ankolvi, Kudaibergen Osmonaliev
Psoriasis is an inflammatory, immune-mediated, persistent, and multifactorial skin disease. Chronic plaque psoriasis is the most common clinical form of psoriasis. Pro-inflammatory cytokines play a primary role in the pathogenicity of this disease. Psoriasis is mainly diagnosed using clinical and dermoscopic examination of the cutaneous lesions, and skin biopsy is used in atypical cases. Psoriasis has no definitive cure. However, several topical agents are effective in managing mild and chronic cases. Combination therapy with these topical agents is more effective than with a single agent...
January 2024: Curēus
https://read.qxmd.com/read/38362228/rapid-resolution-of-non-segmental-vitiligo-in-a-patient-treated-with-abrocitinib-a-case-report
#25
Seyyon Satkunanathan, Mina Boshra, Janis Chang, Reetesh Bose
Vitiligo is a common, autoimmune, depigmenting disorder of the skin. Janus Kinase inhibitors have emerged as promising topical and oral therapeutic options for vitiligo. There have been no reports of vitiligo being treated with oral Abrocitinib, a selective Janus Kinase 1 inhibitor approved for the treatment of moderate to severe atopic dermatitis. Here, we present a 61-year-old male with acrofacial vitiligo who had repigmentation plateau with twice daily tacrolimus 0.1% ointment, oral ginkgo biloba, and oral minipulse prednisone × 4 months; however, they had significant improvement after taking abrocitinib 100 mg per day for 2 months...
2024: SAGE Open Medical Case Reports
https://read.qxmd.com/read/38357778/improved-patient-and-caregiver-reported-outcomes-distinguish-tacrolimus-0-03-from-crisaborole-in-children-with-atopic-dermatitis
#26
JOURNAL ARTICLE
Julie Ryan Wolf, Anita Chen, Jill Wieser, Brad Johnson, Lauren Baughman, Gayin Lee, Eleanor Pope, Abigail Franco, Tanzy Love, Lisa A Beck
BACKGROUND: Atopic dermatitis (AD) is a chronic skin disease that affects 20% of children worldwide and is associated with low patient-reported quality of life (QoL). Crisaborole (CRIS) and tacrolimus 0.03% (TAC) are Food and Drug Administration (FDA)-approved topical treatments for mild to moderate AD with similar clinical efficacy. Utilization of patient-reported outcomes (PROs) may provide meaningful data on the impact of AD treatments on patients and caregivers. This study used PROs to monitor the impact of crisaborole (CRIS) and tacrolimus 0...
February 15, 2024: Journal of the European Academy of Dermatology and Venereology: JEADV
https://read.qxmd.com/read/38348697/assessing-effectiveness-of-adding-niosomal-atorvastatin-1-ointment-to-topical-calcineurin-inhibitor-treatment-in-non-segmental-vitiligo
#27
JOURNAL ARTICLE
Hamed Zartab, Mahin Aflatoonian, Simin Shamsi-Meymandi, Abbas Pardakhty, Ahdie Isazadeh, Alireza Firooz, Rezvan Amiri
BACKGROUND: Treatment of vitiligo is still a big challenge for dermatologists. The efficacy of statins in the treatment of vitiligo is controversial. AIM AND OBJECTIVE: We studied possible therapeutic effect of topical 1% niosomal atorvastatin ointment combined with topical 0.1% tacrolimus in treatment of non-segmental vitiligo. METHODS: This is a triple blind, pilot, randomized placebo-controlled trial (RCT) that was performed in dermatology clinic...
February 13, 2024: Journal of Cosmetic Dermatology
https://read.qxmd.com/read/38345680/efficacy-and-safety-of-topical-tacrolimus-microemulsion-applied-twice-daily-in-patients-with-mild-to-moderate-scalp-psoriasis
#28
JOURNAL ARTICLE
Andreas Pinter, Athanasios Tsianakas, Adina Eichner
INTRODUCTION: Involvement of the scalp is common in psoriasis and severely affects the quality of life of those affected. It is difficult to treat and places special demands on the galenics of a drug formulation. Tacrolimus is a calcineurin inhibitor and is approved as an ointment formulation for the treatment of atopic dermatitis. The efficacy and safety of topically applied tacrolimus have also been studied and proven for psoriasis. However, no proprietary pharmaceutical product is currently approved for this indication...
February 12, 2024: Dermatology and Therapy
https://read.qxmd.com/read/38326166/jak-inhibitors-for-the-treatment-of-vitiligo
#29
REVIEW
Shintaro Inoue, Tamio Suzuki, Shigetoshi Sano, Ichiro Katayama
Vitiligo is an autoimmune disease involving melanocyte-targeting T cells initiated by environmental and genetic factors. Steroids and tacrolimus have been used as topical treatments. Recently, novel topical agents targeting Janus kinase (JAK), a family of tyrosine kinases that regulates cytokine signaling, have emerged. Ruxolitinib is the first approved in vitiligo therapy. Furthermore, ritlecitinib is currently under clinical trials for oral treatment of active vitiligo. In this review, we discuss the possibility of topical JAK inhibitors as promising options for the treatment of vitiligo with regard to their mechanism of action, efficacy and safety...
March 2024: Journal of Dermatological Science
https://read.qxmd.com/read/38323717/comparison-of-the-clinical-efficacy-of-topical-tretinoin-0-05-cream-and-tacrolimus-0-1-ointment-using-iontophoresis-in-the-management-of-palmar-plantar-psoriasis
#30
JOURNAL ARTICLE
Aditya Bubna
BACKGROUND: Palmoplantar psoriasis is a localised variant of psoriasis that maybe resistant to topical therapy, owing to poor penetrability of topical agents at this anatomical site. Modalities enhancing localised cutaneous delivery of drugs could help in solving this problem. Iontophoresis is one such procedure that augments transdermal drug delivery; thus enabling achievement of better, and expeditious therapeutic outcomes. AIM: To compare the therapeutic efficacy and safety of iontophoresis with tretinoin (0...
February 7, 2024: Clinical and Experimental Dermatology
https://read.qxmd.com/read/38309457/topical-tacrolimus-and-mycophenolic-acid-therapy-synergizes-with-low-dose-systemic-immunosuppression-to-sustain-vascularized-composite-allograft-survival
#31
JOURNAL ARTICLE
Firuz G Feturi, Wensheng Zhang, Vasil E Erbas, Liwei Dong, Huseyin Sahin, Zhaoxiang Zhang, Sinan Oksuz, Alexander M Spiess, Mario G Solari, Raman Venkataramanan, Vijay S Gorantla
AIM: The goal of this study was to evaluate whether topical administration of tacrolimus (TAC) and mycophenolic acid (MPA) at the transplant site enables vascularized composite allograft (VCA) survival with significant minimization of the dose and adverse effects of systemic TAC (STAC) immunosuppression. MATERIALS AND METHODS: Lewis (Lew) rats received orthotopic hind limb allotransplants from fully mismatched Brown Norway (BN) donors. Group 1 (Controls) received no treatment...
February 1, 2024: Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/38297923/pimecrolimus-1-cream-for-mild-to-moderate-atopic-dermatitis-a-systematic-review-and-meta-analysis-with-a-focus-on-children-and-sensitive-skin-areas
#32
JOURNAL ARTICLE
Thomas Luger, Chia-Yu Chu, Ayman Elgendy, Sabeera Begum Binti Kader Ibrahim, Nikolay Murashkin, Sandip Ranjan, Zuotao Zhao
This systematic literature review (SLR) and meta-analysis assessed the efficacy and safety of pimecrolimus vs other topical treatments in patients with mild-to-moderate atopic dermatitis (AD), focusing on children and sensitive skin areas. An SLR was conducted in MEDLINE, Embase and Cochrane Library databases on January 15th, 2020, to identify randomized controlled trials (RCTs) with pimecrolimus as a study arm. Another SLR performed on October 5th, 2020 identified RCTs with a crisaborole study arm. Direct pair-wise meta-analysis was used to compare pimecrolimus with vehicle, tacrolimus or topical corticosteroids (TCS; n = 27 studies)...
October 1, 2023: European Journal of Dermatology: EJD
https://read.qxmd.com/read/38291823/non-systemic-medication-for-the-treatment-of-prurigo-nodularis-a-systematic-review
#33
REVIEW
Manas Ranpariya, Mallory L Zaino, Lillian E McCampbell, Tejesh Patel, Steven R Feldman
Prurigo nodularis (PN) is a skin disease characterized by firm, itchy, erythematous lesions. Treatment consists of systemic and non-systemic modes of therapy. Non-systemic forms of treatment are first-line and include topical corticosteroids, topical steroid-sparing agents, and phototherapy. The objective was to review the efficacy of non-systemic treatment used to treat PN. A systematic search was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered with PROSPERO (CRD42023412012)...
January 30, 2024: Journal of Cutaneous Medicine and Surgery
https://read.qxmd.com/read/38291288/topical-5-aminolevulinic-acid-ala-photodynamic-therapy-pdt-for-lichen-sclerosus-of-face-case-report-and-literature-review
#34
REVIEW
Nello Tommasino, Giuseppe Lauletta, Gustavo Spanò, Lorenzo Scaramuzzino, Gaia De Fata Salvatores, Massimiliano Scalvenzi, Luigi Coronella
Lichen sclerosus (LS) is a chronic inflammatory dermatosis typical of the genital region, with rare involvement of extragenital areas and particularly the face. LS therapeutic management is challenging, and common therapies including topical and systemic corticosteroids, topical calcineurin inhibitors, surgery are often ineffective. Herein, we present a case of LS occurred in a 36-year-old girl with facial involvement resistant to therapy with systemic corticosteroids and topical tacrolimus. Considering the involvement of a sensitive area, the young age of the patient, and the consistent clinical experience in using photodynamic therapy for the treatment of facial skin disease, we started a treatment with topical 5-aminolevulinic acid (ALA)-photodynamic therapy (PDT) with a dosage of 37 J/cm2 once a month...
January 31, 2024: Lasers in Medical Science
https://read.qxmd.com/read/38266392/xanthogranulomatous-keratitis-in-a-mixed-breed-dog
#35
JOURNAL ARTICLE
Alexandra Bergen, James Herrmann, Christopher M Reilly
OBJECTIVE: To evaluate the clinical and histopathological features of a case of xanthogranulomatous keratitis in a mixed-breed dog. ANIMAL: Mixed-breed dog. CLINICAL PRESENTATION, PROGRESSION, AND PROCEDURES: An 11-year-old spayed female mixed-breed dog was presented for mild blepharospasm, corneal cloudiness, and increasing conjunctival hyperemia OD. Ophthalmic examination revealed multifocal pink and cream-colored consolidated corneal infiltrative lesions and generalized neovascularization with suspected diagnosis of stromal abscessation...
April 1, 2024: Journal of the American Veterinary Medical Association
https://read.qxmd.com/read/38264905/characterization-of-the-calcineurin-inhibitor-pain-syndrome-in-patients-undergoing-allogeneic-hematopoietic-cell-transplantation
#36
JOURNAL ARTICLE
Craig W Freyer, Alison Carulli, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Mary Ellen Martin, Selina M Luger, David L Porter, Edward A Stadtmauer, Alison W Loren
Calcineurin inhibitor pain syndrome (CIPS) is a rare complication of graft-vs-host disease prophylaxis following allogeneic hematopoietic cell transplant (alloHCT). CIPS presents as severe bilateral lower extremity pain, and the incidence, risk factors, and management of CIPS are poorly characterized.This is a single center retrospective study of patients who received tacrolimus (TAC) following alloHCT to describe the characteristics and management of CIPS and compare to a cohort who did not develop CIPS.Fifteen of 585 alloHCT patients (2...
February 2024: Leukemia & Lymphoma
https://read.qxmd.com/read/38233878/tacrolimus-versus-mycophenolate-for-autoimmune-hepatitis-patients-with-incomplete-response-on-first-line-therapy-tailor-study-a-study-protocol-for-a-phase-iii-open-label-multicentre-randomised-controlled-trial
#37
JOURNAL ARTICLE
Anna E C Stoelinga, Maarten E Tushuizen, Wilbert B van den Hout, Mar D M Rodriguez Girondo, Elsemieke S de Vries, Amar D Levens, Dirk-Jan A R Moes, Tom J G Gevers, Suzanne van der Meer, Hans T Brouwer, Hendrik J M de Jonge, Ynte S de Boer, Ulrich H W Beuers, Adriaan J van der Meer, Aad P van den Berg, Maureen M J Guichelaar, Joost P H Drenth, Bart van Hoek
BACKGROUND: Autoimmune hepatitis (AIH) is a rare, chronic inflammatory disease of the liver. The treatment goal is reaching complete biochemical response (CR), defined as the normalisation of aspartate and alanine aminotransferases and immunoglobulin gamma. Ongoing AIH activity can lead to fibrosis and (decompensated) cirrhosis. Incomplete biochemical response is the most important risk factor for liver transplantation or liver-related mortality. First-line treatment consists of a combination of azathioprine and prednisolone...
January 17, 2024: Trials
https://read.qxmd.com/read/38229798/intermittent-or-sequential-topical-tacrolimus-in-atopic-dermatitis-systematic-review-and-meta-analysis
#38
REVIEW
Sandipan Dhar, Abhishek De, Abhijit Saha, Kruttika R Chitnis, Abhishek Mane, Dhiraj Dhoot, Hanmant Barkate
Topical calcineurin inhibitors (TCIs) and topical corticosteroids (TCS) are the mainstays of flare management for atopic eczema or atopic dermatitis (AD). Tacrolimus (an immunomodulator), belongs to the class of calcineurin inhibitors, with promising efficacy in AD. We performed this systematic review to obtain an up-to-date coverage map of controlled clinical trials of sequential or intermittent treatments with TCI as a therapeutic intervention for AD. Articles of interest were retrieved from PubMed, Google Scholar, and EMBASE published between between January 2000 and March 2023...
December 2023: Curēus
https://read.qxmd.com/read/38226937/immunosuppressive-and-immunomodulating-therapy-for-atopic-dermatitis-in-pregnancy-an-appraisal-of-the-literature
#39
JOURNAL ARTICLE
Aska Drljevic-Nielsen, Sofine Heilskov, Mette S Deleuran, Christian Vestergaard
Atopic dermatitis (AD) is the most common dermatological diagnosis during pregnancy. Treatment of AD during pregnancy can be challenging, due to the unpredictable course and the fact that the therapy needs to be safe for both the mother and the fetus. Here we present an up-to-date appraisal of the literature on the treatment options available for AD in patients planning pregnancy, during pregnancy, and during breastfeeding. All patients with AD are recommended to supplement any medical treatment with daily applications of emollients...
January 16, 2024: Italian journal of dermatology and venereology
https://read.qxmd.com/read/38226116/long-term-clinical-outcome-of-tacrolimus-skin-ointment-0-03-for-the-treatment-of-vernal-keratoconjunctivitis-a-quasi-experimental-study
#40
JOURNAL ARTICLE
Warda Ali, Saad Alam Khan, Fahim Ullah Khan, Shama Khan, Wajid A Khan, Rabeeah Zafar, Muhammad A Moqeet
Background Vernal keratoconjunctivitis (VKC) is an allergic conjunctival inflammation with severe ocular complications if left untreated. The current management regimen is plagued with adverse effects, long-term problems, and clinical relapses. Tacrolimus offers an alternative treatment option, and long-term studies are needed to determine its efficacy. Methods A two-year follow-up based study was conducted on moderate to severe VKC patients, who were prescribed tacrolimus skin ointment. The 5-5-5 exacerbation scale was used for the monitoring and grading severity of the disease...
December 2023: Curēus
keyword
keyword
71401
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.